Please login (Members) to view content or
(Nonmembers) this article.
No votes yet
ONS Guidelines Article
Online Exclusive Article

Management of Opioid-Induced and Non–Opioid-Related Constipation in Patients With Cancer: Systematic Review and Meta-Analysis

Pamela K. Ginex
Brian J. Hanson
Kristine B. LeFebvre
Yufen Lin
Kerri A. Moriarty
Christine Maloney
Mark Vrabel
Rebecca L. Morgan
ONF 2020, 47(6), E211-E224 DOI: 10.1188/20.ONF.E211-E224

Problem Identification: A systematic review and meta-analysis was conducted to inform the development of national clinical practice guidelines on the management of cancer constipation.

Literature Search: PubMed®, Wiley Cochrane Library, and CINAHL® were searched for studies published from May 2009 to May 2019.

Data Evaluation: Two investigators independently reviewed and extracted data from eligible studies. The Cochrane Collaboration risk-of-bias tool was used, and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to assess the certainty of the evidence.

Synthesis: For patients with cancer and opioid-induced constipation, moderate benefit was found for osmotic or stimulant laxatives; small benefit was found for methylnaltrexone, naldemedine, and electroacupuncture. For patients with cancer and non–opioid-related constipation, moderate benefit was found for naloxegol, prucalopride, lubiprostone, and linaclotide; trivial benefit was found for acupuncture.

Implications for Practice: Effective strategies for managing opioid-induced and non–opioid-related constipation in patients with cancer include lifestyle, pharmacologic, and complementary approaches.

Supplemental material can be found at

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or